Hemab Therapeutics Holdings, Inc. Common Stock (COAG)
Hemab Therapeutics Holdings, Inc. Common Stock operates in the Biotechnology industry of the Healthcare sector, headquartered in Cambridge, MA, US. The stock last traded at $30.07, down 7.53% on the session, giving a market capitalisation of $1.40B. On trailing twelve-month figures it carries a trailing P/E of -22.95, a net margin of 0.0%. Its beta of 1.85 implies it has historically moved more than the broad market.
Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience for patients through innovative therapies. The company's leading pipeline candidate is HMB-001, a bispecific antibody. This asset is currently undergoing Phase 1/2 clinical trials for the preventive management of Glanzmann thrombasthenia and has progressed to Phase 2 for the prophylactic treatment of Factor VII deficiency. Additionally, Hemab is advancing HMB-002, a monovalent antibody, through Phase 1/2 clinical development. This drug is designed for the subcutaneous prophylactic treatment of Von Willebrand disease. Beyond these clinical assets, the company actively pursues numerous preclinical and discovery-stage programs. Established in 2020, Hemab Therapeutics Holdings, Inc. maintains its headquarters in Cambridge, Massachusetts.
Hemab Therapeutics Holdings, Inc. Common Stock is most often compared with the following Healthcare names: